AA
CNTA

ALPS Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

ALPS Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-51,503
Closed -$207K – 1037
2022
Q3 		$207K Sell
51,503
-4,282
-8% -$19.6K ﹤0.01% 1002
2022
Q2 		$272K Buy
+55,785
New +$357K ﹤0.01% 892

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TWM
Tanager Wealth Management Goring On Thames, United Kingdom $1.15B AUM 19.91% 1-Year Est. Return

ALPS Advisors's CNTA Position: Q4 2022 in Review

ALPS Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q4 2022, closing a stake of 51,503 shares — an estimated $207K sold.

ALPS Advisors first reported a position in CNTA in Q2 2022 and held it in 2 quarters. The position peaked at $272K in Q2 2022. 44 funds tracked by Wall St. Rank hold CNTA as of Q4 2022.

  • ALPS Advisors reported no remaining Centessa Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • ALPS Advisors sold 51,503 Centessa Pharmaceuticals shares in Q4 2022, an estimated $207K.
  • ALPS Advisors first reported a position in Centessa Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • ALPS Advisors's Centessa Pharmaceuticals position peaked at $272K in Q2 2022.
  • 44 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q4 2022.

Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.